Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF-alpha therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Methotrexate (Primary) ; Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms REFLEX
- Sponsors Biogen; Roche
- 03 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00468546).
- 03 May 2010 Two-year radiographic results have been published in Annals of the Rheumatic Diseases (2010;69:1158-1161 doi:10.1136/ard.2009.119222; published online first 3 May 2010).
- 16 Mar 2010 Planned end date (Jun 2011) added as reported by ClinicalTrials.gov.